A review on nanosuspensions in drug delivery

International Journal of Pharma and Bio Sciences

Volumn 2, Issue 1, 2011, Pages 549-558

  Prabhakar, Ch ^a   Bala Krishna, K ^b  

^a Chilkur Balaji College of Pharmacy   (India)

^b Nova College Pharmacy   (India)

Author keywords

Crystalline state; Disperse system; Homogenization; Milling; Nanosuspension; Precipitation; Saturation solubility; Zeta potential

Indexed keywords

AMPHOTERICIN B; CLOFAZIMINE; CLORICROMEN; DANAZOL; IBUPROFEN; LIPID EMULSION; NAPROXEN; STABILIZING AGENT;

DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG TISSUE LEVEL; GRINDING; MICROEMULSION; MUCOADHESION; NANOSUSPENSION; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRECIPITATION; REVIEW; STRUCTURE ANALYSIS; SUSPENSION; ZETA POTENTIAL;

EID: 84855338109     PISSN: None     EISSN: 09756299     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. T. Lenhardt, G. Vergnault, P. Grenier, D. Scherer, and P. Langguth1, Evaluation of Nanosuspensions for Absorption Enhancement of Poorly Soluble Drugs: In Vitro Transport Studies Across Intestinal Epithelial Monolayers. The AAPS Journal, Vol. 10, No. 3, September 2008 (# 2008)DOI: 10.1208/s12248-008-9050-7
2. N Arunkumar, M Deecaraman and C Rani, Nanosuspension technology and its applications in drug delivery, Asian journal of pharmaceutics, Year: 2009, Volume: 3, Issue: 3, Page: 168-173
3. Nagaraju. P*, Krishnachaithanya. K, Srinivas. V.D.N and Padma. S.V.N, Nanosuspensions: A Promising Drug Delivery Systems, International Journal of Pharmaceutical Sciences and Nanotechnology, Volume 2, Issue 4,January - March 2010
4. Suryakanta Nayak*, Dibyasundar Panda, Jagannath Sahoo, Nanosuspension:A novel drug delivery system, Journal of Pharmacy Research Vol.3.Issue 2.February 2010 241-246
5. Xiaohui Pu, Jin Sun, Mo Li and Zhonggui He, Formulation of Nanosuspensions as a New Approach for the Delivery of Poorly, Current Nanoscience, 2009, 5, 417-427, Bentham Science Publishers Ltd.
6. Mahendra NAKARANI*, Priyal PATEL, Jayvadan PATEL, Pankaj PATEL, Rayasa S. R. MURTHY and Subhash S. VAGHANI, Cyclosporine A-Nanosuspension Formulation, Characterization and In Vivo Comparison with a Marketed Formulation, Sci Pharm. 2010; 78: 345-361 doi:10.3797/scipharm.0908-12
7. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: Absolute oralbioavailability of nanocrystalline danazol in beagle dogs.Int J Pharm. 1995; 125(1): 91-97.doi:10.1016/0378-5173(95)00122-Y
8. Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Müller RH, Ehlers S. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemoth. 2000; 45: 77-83. doi:10.1093/jac/45.1.77
9. Rosario P, Claudio B, Piera, F, Adriana M., Antonina, P, Giovanni P. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci. 2002; 16: 53-61. doi:10.1016/S0928-0987(02)00057-X
10. 10.Jacobs C, Muller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res. 2002; 19: 189-194. doi:10.1023/A:1014276917363
11. Panayiotis P. Constantinides, Mahesh V. Chaubal and Robert Shorr, Advances in lipid nanodispersions for parenteral drug delivery and targeting, Advanced Drug Delivery Reviews 60 (2008) 757-767
12. Shobha R, Hiremath R, Hota A, Nanoparticles as drug delivery systems, Ind.J.Pharm.Sci,61,1999, 69-75.
13. Mehnertw, Mader K. Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug Deliv. Rev, 47, 2000, 165-96.
14. Suryakanta Nayak*, Dibyasundar Panda, Jagannath Sahoo, Nanosuspension:A novel drug delivery system, Journal of Pharmacy Research Vol.3.Issue 2.February 2010 241-246
15. Senthil Kumar. C, Vedha Hari. B.N, Sharavanan. S.P, Subramanian. N, Punitha. S and Senthil Kumar. V, Novel Metronidazole Nanosuspension as a Controlled Drug Delivery System for Anthelmintic Activity, Journal of Pharmacy Research Vol.3.Issue 10.October 2010
16. J. B. Dressman, G. L. Amidon, C. Reppas, and V. P. Shah.Dissolution testing as a prognostic tool for oral drug absorption:immediate release dosage forms. Pharm Res. 15(1):11-22 (1998).
17. M. Mosharraf, T. Sebhatu, and C. Nystrom. The effects of disordered structure on the solubility and dissolution rates of some hydrophilic, sparingly soluble drugs. Int J Pharm. 177(1): 29-51 (1999)
18. R. H. Muller, C. Jacobs, and O. Kayser. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect forthe future. Adv Drug Deliv Rev. 47(1):3-19 (2001).
19. K. Kreuter. Peroral administration of nanoparticles. Advanced Drug Delivery Reviews. 7:71-86 (1991).
20. G. Wilson. Cell culture techniques for the study of drug transport. Eur J Drug Metab Pharmacokinet. 15(2):159-163 (1990).
21. Jiraporn CHINGUNPITUK, Nanosuspension Technology for Drug Delivery, Sci & Tech 2007; 4(2): 139-153
22. Grau, M.J.; Kayser, O.; Müller, R.H. Nanosuspensions of poorly solubledrugs -reproducibility of small-scale production. Int. J. Pharm., 2000, 196,155-157.
23. RH Müller, C Jacobs and O Kayer. Nanosuspensions for the formulation of poorly soluble drugs. In: F Nielloud, G Marti-Mestres (ed). Pharmaceutical emulsion and suspension. New York, Marcel Dekker, 2000, p. 383-407.
24. GG Liversidge and P Conzentino. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 1995; 125, 309-13.
25. GG Liversidge, KC Cundy, JF Bishop and DA Czekai. Surface modified drug nanoparticles. US Patent 5, 145, 684, 199.
26. Matteucci, M.E.; Brettmann, B.K.; Rogers, T.L.; Elder, E.J.; Williams, R.O.3rd; Johnston, K.P. Design of potent amorphous drug nanoparticles for rapidgeneration of highly supersaturated media. Mol. Pharm., 2007, 4(5),782-793.
27. Myerson, A.S.; Ginde, R. Handbook of Industrial Crystallization. Butterworth-Heinemann, 1992, pp. 45-46.
28. Bodmeier, R.; McGinity, J.M. Solvent selection in the preparation of poly(DLlactide) microspheres prepared by solvent evaporation method. Int. J.Pharm., 1998, 43, 179-186.
29. VB Patravale, AA Date and RM Kulkarni. Nanosuspension: a promising drug delivery strategy. J. Pharm. Pharmacol. 2004; 56, 827 40.
30. M Trotta, M Gallarate, ME Carlotti and S Morel. Preparation of griseofulvin nanoparticles from water-dilutable microemulsions. Int. J. Pharm. 2003; 254, 235-42.
31. V. B. Patravale, Abhijit A. Date and R. M. Kulkarni, Nanosuspensions: a promising drug delivery strategy, JPP 2004, 56: 827-840
32. Shah T, Patel D, Hirani J, Amin AF. Nanosuspensions as a drug delivery systems-A comprehensice review. Drug Del Tech 2007;7:42-53.
33. Chen, Y.; Liu, J.; Yang, X.; Zhao, X.; Xu, H. Oleanolic acid nanosuspensions: preparation, in-vitro characterization and enhanced hepatoprotective effect. J. Pharm. Pharmacol., 2005, 57, 259-264.
34. Teeranachaideekul, V.; Junyaprasert, V.B.; Souto, E.B.; Móller, R.H. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Int. J. Pharm., 2008, 354, 227-234.
35. Setler P. Identifying new oral technologies to meet your drug delivery needs for the delivery of peptides and proteins and poorly soluble molecules. IIR Limited, Drug delivery systems London: 1999.
36. Liversidge GC. Paper presented at the 23 rd International symposium of the Controlled Release Bioactive Materials Society. Workshop on Particulate Drug Delivery Systems; 1996.
37. Kayser O, Olbrich C, Yardley V, Kiderten Ap, Croft SL. Formulation of amphotericin-B as nanosuspension for oral administration. Int J Pharm 2003;254:73-5.
38. Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Móller RH, et al. Preparation of a clofaziminenanosuspensions for intravenous use and evaluation of its therapeutic efficacy in murine mycobacterium avium infection. J Antimicrob Chemother 2000;45:77-83.
39. Jacobs C, Kayder O, Muller RH. Nanosuspensions as a new approach for the formulation of poorly soluble drug tarazepide. Int J Pharm 2000;196:161-4.
40. Muller RH, Jacobs C. Production and Characterization of Budenoside nanosuspension for pulmonary administration. Pharm Res 2002;19:189-94.
41. Pignatello R, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G. Preparation and characterization of Eudragit retard nanosuspensions for the ocular delivery of cloricromene. AAPS Pharmscitech 2006;7:E27.
42. Kayser O. Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against Leishmania infected macrophages. Int J Pharm 2000;196:253-6.
43. Schφler N, Krause K, Kayser O, Móller RH, Borner K, Hahn H, et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplamosis. Antimicrob Agents Chemother 2001;45:1771-9.
44. Ponchel G, Montisci MJ, Dembri A, Durrer C, Duchkne. D. Mucoadhesion of colloidal particulate systems in the gastrointestinal tract. Eur J Pharm Biopharm 1997; 44:25-31.